WO1996030016A3 - Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases - Google Patents

Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases Download PDF

Info

Publication number
WO1996030016A3
WO1996030016A3 PCT/EP1996/001229 EP9601229W WO9630016A3 WO 1996030016 A3 WO1996030016 A3 WO 1996030016A3 EP 9601229 W EP9601229 W EP 9601229W WO 9630016 A3 WO9630016 A3 WO 9630016A3
Authority
WO
WIPO (PCT)
Prior art keywords
ridogrel
inflammatory bowel
formulations
bowel diseases
treatment
Prior art date
Application number
PCT/EP1996/001229
Other languages
French (fr)
Other versions
WO1996030016A2 (en
Inventor
Maria-Helena Joris J Verlinden
Original Assignee
Janssen Pharmaceutica Nv
Verlinden Maria Helena Joris J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Verlinden Maria Helena Joris J filed Critical Janssen Pharmaceutica Nv
Priority to JP8528894A priority Critical patent/JPH10511097A/en
Priority to AU53974/96A priority patent/AU5397496A/en
Priority to EP96910921A priority patent/EP0817631A2/en
Publication of WO1996030016A2 publication Critical patent/WO1996030016A2/en
Publication of WO1996030016A3 publication Critical patent/WO1996030016A3/en
Priority to MXPA/A/1997/007394A priority patent/MXPA97007394A/en
Priority to NO974486A priority patent/NO974486L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to the use of ridogrel for the manufacture of a medicament for treating inflammatory bowel diseases, wherein ridogrel is administered in a daily dose from 0.01 mg/kg body weight to 0.5 mg/kg body weight; pharmaceutical compositions comprising ridogrel.
PCT/EP1996/001229 1995-03-28 1996-03-18 Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases WO1996030016A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP8528894A JPH10511097A (en) 1995-03-28 1996-03-18 Low-dose lidogrel formulations and their use for the treatment of inflammatory bowel disease
AU53974/96A AU5397496A (en) 1995-03-28 1996-03-18 Low dose ridogrel formulations and their use for the treatme nt of inflammatory bowel diseases
EP96910921A EP0817631A2 (en) 1995-03-28 1996-03-18 Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
MXPA/A/1997/007394A MXPA97007394A (en) 1995-03-28 1997-09-26 Formulations of low dose ridogrel and its use the treatment of inflamator intestinal diseases
NO974486A NO974486L (en) 1995-03-28 1997-09-29 Low-dose "Ridogrel" formulations and their use in the treatment of intestinal inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200768.0 1995-03-28
EP95200768 1995-03-28

Publications (2)

Publication Number Publication Date
WO1996030016A2 WO1996030016A2 (en) 1996-10-03
WO1996030016A3 true WO1996030016A3 (en) 1997-01-30

Family

ID=8220134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/001229 WO1996030016A2 (en) 1995-03-28 1996-03-18 Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases

Country Status (10)

Country Link
EP (1) EP0817631A2 (en)
JP (1) JPH10511097A (en)
AR (1) AR002727A1 (en)
AU (1) AU5397496A (en)
CA (1) CA2215160A1 (en)
HU (1) HUP9900309A3 (en)
IL (1) IL117670A (en)
NO (1) NO974486L (en)
WO (1) WO1996030016A2 (en)
ZA (1) ZA962461B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
EP1370244A1 (en) * 2001-03-12 2003-12-17 Novo Nordisk A/S Novel tablets and capsules and a process for its preparation
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
UA105037C2 (en) 2009-02-16 2014-04-10 Джуліані Інтернешнл Лімітед Methods of treating hair related conditions
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
EA201491894A1 (en) 2012-04-18 2015-02-27 Ногра Фарма Лимитед METHODS OF TREATMENT OF Lactose Intolerance
WO2017046343A1 (en) * 2015-09-17 2017-03-23 Nogra Pharma Limited Compositions for rectal administration in the treatment of ulcerative colitis and methods of using same
KR20210125047A (en) 2019-02-08 2021-10-15 노그라 파마 리미티드 Process for the preparation of 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0221601A1 (en) * 1985-11-04 1987-05-13 Janssen Pharmaceutica N.V. [[[(3-Pyridinyl)methylen]amino]oxy]alkanoic acids and esters

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0221601A1 (en) * 1985-11-04 1987-05-13 Janssen Pharmaceutica N.V. [[[(3-Pyridinyl)methylen]amino]oxy]alkanoic acids and esters

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CASELLAS F ET AL: "A SELECTIVE THROMBOXANE SYNTHETASE INHIBITOR IMPROVES CHRONIC ULCERATIVE COLITIS", 94TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION, BOSTON, MASSACHUSETTS, USA, MAY 15-21, 1993. GASTROENTEROLOGY, 104 (4 SUPPL.). 1993. A677., XP000612204 *
CASELLAS F ET AL: "IN-VIVO QUANTIFICATION OF INTRACOLONIC EICOSANOID RELEASE IN ACTIVE CHRONIC ULCERATIVE COLITIS AFTER INHIBITION OF THROMBOXANE SYNTHETASE BY RIDOGREL", DIGESTIVE DISEASE WEEK AND THE 93RD ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION, SAN FRANCISCO, CALIFORNIA, USA, MAY 9-15, 1992. GASTROENTEROLOGY, 102 (4 PART 2). 1992. A601., XP000612207 *
KEITH JC JR ET AL: "Effects of ridogrel on the prostacyclin-thromboxane ratio in nulliparous third trimester-pregnant rhesus monkeys.", PROSTAGLANDINS, JUN 1993, 45 (6) P547-55, UNITED STATES, XP000611801 *
KEITH JC JR ET AL: "Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension.", PROSTAGLANDINS, MAR 1994, 47 (3) P247-63, UNITED STATES, XP000611800 *
SPITZ B. ET AL: "Differential inhibition of vascular prostacyclin and platelet thromboxane synthesis by different doses aspirin and by the thromboxane inhibitor ridogrel (R 68070)", CLIN. EXP. HYPERTENS. PART B HYPERTENS. PREGNANCY, 1991, 10/3 (371-383), USA, XP000612222 *
VANDEPLASSCHE G ET AL: "Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis.", J CARDIOVASC PHARMACOL, JAN 1993, 21 (1) P56-69, UNITED STATES, XP000611801 *
VILASECA J ET AL: "Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis.", GASTROENTEROLOGY, FEB 1990, 98 (2) P269-77, UNITED STATES, XP000610998 *

Also Published As

Publication number Publication date
IL117670A0 (en) 1996-07-23
MX9707394A (en) 1997-11-29
AR002727A1 (en) 1998-04-29
JPH10511097A (en) 1998-10-27
WO1996030016A2 (en) 1996-10-03
HUP9900309A2 (en) 1999-05-28
NO974486D0 (en) 1997-09-29
NO974486L (en) 1997-09-29
AU5397496A (en) 1996-10-16
ZA962461B (en) 1997-09-29
CA2215160A1 (en) 1996-10-03
IL117670A (en) 2000-02-29
HUP9900309A3 (en) 1999-11-29
EP0817631A2 (en) 1998-01-14

Similar Documents

Publication Publication Date Title
EP0254067A3 (en) Composition for metastasis prevention
NZ514077A (en) Treatment of Α-galactosidase A deficiency
MY125662A (en) Pharmaceutical formulations containing darifenacin
MX9700081A (en) Tacrine pharmaceutical compositions.
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
EP1658858A3 (en) Use of botulinum toxin for the treatment of unstable bladder
BG66114B1 (en) Pharmaceutical composition with drospirenone as contraceptive
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
HUT68498A (en) L-dopa ester compositions and process to prepare them
CA2229282A1 (en) Use of hyaluronic acid as an immunosuppressant
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
NZ318282A (en) Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
CA2143413A1 (en) Local Drug Delivery Film, for Periodontal Treatment
EP1201246A3 (en) Use of Thrombopoietin as a medicament for the therapy and prevention of thrombocytopenia
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
CA2139385A1 (en) Products containing g-csf and tnf binding protein
HUP9801241A2 (en) Azathioprine compositions for colonic administration and process for their preparation
JP2004537500A5 (en)
WO1996030016A3 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
CA2180178A1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
JP2002523437A5 (en)
PL339774A1 (en) Method of preventing nephrotoxicity caused by cephalosporins and tacrolimus
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
EG17992A (en) Preparation of a medicament for arthritis and theumatism

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96192851.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU BB BG BR CA CN CZ EE GE HU IS JP KG KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU BB BG BR CA CN CZ EE GE HU IS JP KG KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1019970703705

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1996910921

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 913274

Country of ref document: US

Date of ref document: 19970909

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2215160

Country of ref document: CA

Ref document number: 2215160

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 305853

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/007394

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1996910921

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970703705

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996910921

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019970703705

Country of ref document: KR